However, both tests determined whether a tumor is a potential target for anti-HER-2 treatment response in the metastatic setting, which is only achieved in about 50% of cases, while >25% of women treated with neoadjuvant anti HER-2 therapy relapse within the first ten years of diagnosis (11). The gene discussed is ERBB2; the disease is neoplasm.